Company Profile
树正气 高效率 敢担当 有作为
Overview
Understand the development history and corporate strength of Livzon New North River Pharmaceutical Co., Ltd.
ㅤㅤLivzon Pharmaceutical Group New North River Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in microbial fermentation-semi-synthesis technology. It primarily researches, develops, produces, and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and biopharmaceutical preparations. Its products are widely used in cardiovascular and cerebrovascular diseases, organ transplantation, anti-infection, hypoglycemic agents, and high-end animal health products. ㅤㅤThe company currently has two plants: the old plant is located on Renmin Road, Qingcheng District, Qingyuan City, covering an area of 72,190 square meters; the new plant is located at No. 9, Shilong Avenue, Shijiao Town, covering an area of 70,895 square meters. ㅤㅤNew North River Pharmaceutical is a high-tech enterprise, awarded the national 'Green Factory' title, a key laboratory enterprise in Guangdong Province, a Guangdong Provincial Innovative Enterprise, a Guangdong Provincial Specialized and Innovative SME, a Guangdong Provincial High-Growth SME, and a Guangdong Provincial Export Brand Enterprise. It possesses a provincial-level enterprise technology center, a Guangdong Provincial Fermentation Pharmaceutical Engineering Technology Research and Development Center, a Guangdong Provincial Veterinary API Engineering Technology Research and Development Center, and the Guangdong New North River Veterinary API Modern Agricultural Science and Technology Innovation Center. It is a national intellectual property advantage enterprise, a Guangdong Provincial intellectual property demonstration enterprise, a Qingyuan City benchmark high-tech enterprise, and also has a Guangdong Provincial postdoctoral workstation. ㅤㅤThe company has passed certifications for its Intellectual Property Management System (standard GB/T29490-2013), Environmental Management System (standard ISO 14001:2015), Occupational Health and Safety Management System (standard OHSAS 18001:2007), and Energy Management System (standard ISO 50001:2018). In 2023, the project 'Key Technology Research and Industrialization of High-End Pet Drug Moxicidin' won the 2022 Guangdong Provincial Science and Technology Achievement Promotion Award.
Core Advantages
about.company.advantages_subtitle
Modern Production Base
The company has two manufacturing facilities. The old factory is located at Renmin 1st Road, Qingcheng District, Qingyuan City (covering 72,190㎡). The new factory is at No.9 Shilong Avenue, Shijiao Town (covering 70,895㎡). Key products including Acarbose, Tobramycin, Moxidectin have passed US FDA inspection, China GMP certification, and obtained EU CEP certificates, US DMF and VMF numbers.
Industry-Academia-Research Collaboration
Maintains long-term cooperation with renowned universities and research institutions including Zhejiang University, South China Sea Institute of Oceanology (CAS), Guangdong Academy of Agricultural Sciences, Jilin University, Sun Yat-sen University, Wuhan University, and South China University of Technology.
Strong R&D Capability
Annual R&D investment exceeds 10 million RMB. The company holds 55 authorized invention patents, 1 computer software copyright, and 20 pending invention patent applications. It has established several provincial-level R&D platforms including Guangdong Provincial Engineering Technology Research and Development Center for Fermentation Pharmaceuticals.
Global Market Reach
Products are sold internationally with significant market share in North America, South America, Europe, and Southeast Asia. The company is deeply integrated into the API supply chain of Global 500 pharmaceutical enterprises, maintaining long-term strategic partnerships with MSD, Elanco, Novartis, and other world-renowned companies.